awmsg logo



pasireotide pamoate (Signifor®)


Reference No. 1726

Publication date:
12/12/2017


Appraisal information

pasireotide pamoate (Signifor®) 10 mg powder and solvent for suspension for injection
pasireotide pamoate (Signifor®) 20 mg powder and solvent for suspension for injection
pasireotide pamoate (Signifor®) 30 mg powder and solvent for suspension for injection
pasireotide pamoate (Signifor®) 40 mg powder and solvent for suspension for injection
pasireotide pamoate (Signifor®) 60 mg powder and solvent for suspension for injection


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 08/12/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, pasireotide (Signifor®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.
Statement of Advice (SOA)
Download